News
The rising stars of pregnancy apps
One of the fastest growth drivers in feminine health technology is apps. From period-tracking to women’s fitness, online nannies and menopause support, femtech apps are bringing their A-game. The biggest players? Pregnancy apps. With 385,000 babies born every day, pregnancy is big business. Those kinds of figures are hard to ignore and the tech industry is listening.
Engaging with pregnancy apps is becoming a routine part of the maternal experience. There are hundreds of options available, from simple growth trackers to medical advisors, social communities and the answers to any question you could ever think of.
BabyCentre is one of the most popular. It is an award-winning platform with millions of unique users and is, according to Forbes, the best pregnancy tracking app out there.
The user not only gets 3D renderings of their baby’s development in the womb but also access to a social network connected to other expectant women, along with a whole host of related information and resources.
It is available in five languages and any health information is approved by its own Medical Advisory Board and certified by the NHS England Information Standard.
Trackers like BabyCentre make up the bulk of the app market, but they are just one of the options available.
Pregnancy and motherhood can be lonely, so having a group of people to offer support often makes a big difference.
That’s the idea behind Peanut, otherwise known as the Tinder for expectant mothers, which comes in at a respectable number nine on the GoodHousekeeping list of the 18 best pregnancy apps. Peanut enables users to connect with people in the same area who are also going through similar circumstances, be that pregnancy, menopause or motherhood.
It has thousands of users across the globe and Founder and CEO Michelle Kennedy believes they must ensure no woman has to figure it out on their own.
Expectful is another big name on the circuit. The app aims to be a one-stop-shop for affordable, accessible and enjoyable maternal wellness support and boasts specialists in lactation, sleep, nutrition, mental health and fertility.
Within the app are meditations, events such as fitness classes and live Q&As, and drop-in support groups. The app is another of those featured on Good Housekeeping’s 18 best pregnancy apps.
What To Expect hits the top-rated lists for a few publications, including Women’s Health, Cosmopolitan, and Forbes. It is a very popular app that not only offers a weekly pregnancy tracker but also supports users in the first year of parenthood and beyond.
It advises on products, such as car seats and pushchairs, where it links community reviews and puts them into ‘best of’ lists. Ever wondered where the ’16 weeks, the size of a cherry’ comparison comes from? You can thank What To Expect for that.
With Glow, both the user and their partner can use the app to track the pregnancy together.
There are birth stories, bump pictures and product reviews via the community, as well as appointment reminders, and pregnancy stats.
It also links with Apple Health and My Fitness Pal for full integration.
Also highly rated and providing very similar services are the likes of Sprout, Ovia, Hello Belly and The Bump.
Ultimately, the app a user chooses comes down to personal preference, whether that be the services it provides, the interface or content type.
Why are they so popular?
Pregnancy is a complex time. It brings excitement and fear bundled together with babygrows, nurseries and week-by-week fruit comparisons – and it is a multi-million-pound industry.
And while questions may be raised over marketing to women at a uniquely vulnerable time of their lives, the fact remains that knowledge is power – and that’s what pregnancy apps are sharing.
The breadth and depth of support pregnancy apps offer blow traditional healthcare out of the water. Most are either free with ads or have a subscription fee, which is a small price to pay for access to an extensive support network on demand.
With an ever-increasing user base, apps have the potential to change maternal care and experiences of pregnancy for the better.
Given their popularity and the rising number of users, there is a very real potential for traditional healthcare to adopt or recommend apps into routine care. Bridging the gap between technology and health information would have an enormous impact on the provision of healthcare.
For some users, apps may be more accessible than traditional healthcare. For others, they may provide a community of people going through the same experience. And for others, they can offer answers to questions they may have.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur5 days agoUS startup builds wearable hormone tracker
-
Wellness2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Entrepreneur4 weeks agoVerdane invest in Clue to accelerate the future of women’s health







5 Comments